Search results
Showing 8161 to 8175 of 8944 results
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]
Discontinued Reference number: GID-TA11647
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
This guidance has been updated and replaced by NICE's technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242) and bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
This guidance has been updated and replaced by NICE's technology appraisal guidance on bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).
Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)
This guidance has been updated and replaced by NICE HealthTech guidance 770.
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Discontinued Reference number: GID-TA10694
Discontinued Reference number: GID-TA10843
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
In development Reference number: GID-TA10774 Expected publication date: TBC
In development Reference number: GID-TA11581 Expected publication date: TBC
In development Reference number: GID-TA11884 Expected publication date: TBC
In development Reference number: GID-TA11008 Expected publication date: TBC
Discontinued Reference number: GID-IPG10417
Gantenerumab for treating early Alzheimer's disease [ID6142]
In development Reference number: GID-TA11269 Expected publication date: TBC
In development Reference number: GID-TA11500 Expected publication date: TBC
In development Reference number: GID-TA11560 Expected publication date: TBC